UCB Announces Availability Of Single-Injection Administration Option For BIMZELX - Quick Facts

(RTTNews) - UCB announced that a single-injection 2 mL prefilled syringe and autoinjector, each containing 320 mg of BIMZELX is now available. These are in addition to the 1 mL device administration options, each containing 160 mg of BIMZELX. The company noted that patients requiring a 320 mg dose of BIMZELX will have options for single-injection administration.

Camille Lee, Head of U.S. Immunology, UCB, said: "With the addition of a single-injection administration regimen, we are further expanding options and enhancing the treatment experience for individuals with moderate-to-severe plaque psoriasis, active psoriatic arthritis with coexistent moderate-to-severe plaque psoriasis, and moderate-to-severe hidradenitis suppurativa who receive a 320 mg dose of BIMZELX."

For More Such Health News, visit rttnews.com.